In more details, NSCLC patients with KRAS G12/G13-mutant cfDNA had significantly higher risk of relapse ((HR) = 3.42, (95% CI) = 1.92–6.07, p < 0.001) and significantly increased risk of death ((HR) = 2.72, (95% CI) = 1.55–4.77, p < 0.001) over time, compared to the patients in the KRAS G12/G13-wild type cfDNA group. Here, KRAS is linked to non-small cell lung carcinoma.